Most companies in the life science industry describe themselves as patient centric. At Genentech, that value is more than just a verbal commitment, it’s a lived practice that enjoys company-wide support. Dana Anselmo was tasked to establish a permanent link to the patient community that would help guide Genentech’s corporate strategy to incorporate patient and caregiver needs. To accomplish this, Dana partnered with Snow to create and define her company’s Patient Co-Creation Council (PCC). The PCC’s job is to develop products, services, and solutions for patients with patients—across all of Genentech’s treatment categories. The goal is to ensure seamless, consistent, and meaningful experiences for patients and care partners.
The PCC is composed of a diverse group of patients and care partners with varying conditions and at different points in their treatment journeys, allowing Genentech to gather various perspectives. It currently boasts 135 (and counting) members and has actively recruited and built its “family” through 2023.
The PCC supports larger initiatives within Genentech, so that at the start of each project, marketers are reaching out to the Council, giving weight to the voice of the patient from the beginning. The gained insights inform all patient-facing informational products in the market, from support services to educational materials and discussion guides.
The PCC has managed to complete 17 projects to date in 2024, including a full-week Sprint that included 20 patients and care partners from different therapeutic areas, identifying opportunities, finding solutions, and co-creating content for Genentech to utilize in 2024 and beyond.
